Skip to main content
. Author manuscript; available in PMC: 2011 May 3.
Published in final edited form as: Cancer Treat Res. 2009;151:139–161. doi: 10.1007/978-0-387-75115-3_10

Table 3. Ongoing clinical trials of ovarian ablation/suppression.

Trial Patient population Intervention
ABCSG-12 Premenopausal
Stage I/II/III
HR+		 G + A
vs
G + A + Z
vs
G + T
vs
G + T + Z
IBSCG 24-02/BIG 2-02: SOFT Premenopausal
HR+
No adjuvant chemotherapy or premenopausal after adjuvant chemotherapy		 T
vs
OS + T
vs
OS + AI
IBSCG 25-02/BIG 3-02: TEXT Premenopausal women with HR+ tumors who require OS with or without chemotherapy from the start of adjuvant therapy OS + T
vs
OS + AI

ABCSG = Adjuvant Breast Cancer Study Group; BIG = Breast International Group; HR = hormone receptor; G = Goserelin; A = anastrozole; Z = Zolendronate; T = Tamoxifen; IBSCG = International Breast Cancer Study Group; SOFT = Suppression of Ovarian Function Trial; AI = aromatase inhibitor; TEXT = Tamoxifen and Exemestane Trial